Vaxart Files Additional Proxy Materials
Ticker: VXRT · Form: DEFA14A · Filed: May 16, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | DEFA14A |
| Filed Date | May 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, regulatory, company-history
TL;DR
Vaxart dropped more proxy docs, shareholders need to pay attention.
AI Summary
Vaxart, Inc. filed a Definitive Additional Materials proxy statement on May 16, 2025. This filing relates to the company's proxy materials, indicating it's providing supplementary information to shareholders. The company, formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is based in South San Francisco, CA.
Why It Matters
This filing indicates Vaxart is providing further information to shareholders regarding upcoming decisions or proposals, which could impact their voting decisions on corporate matters.
Risk Assessment
Risk Level: low — This is a routine filing of additional proxy materials, not indicating any immediate financial or operational risk.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former company name
- Biota Pharmaceuticals, Inc. (company) — Former company name
- NABI BIOPHARMACEUTICALS (company) — Former company name
- South San Francisco, CA (location) — Business address
FAQ
What type of filing is this DEFA14A for Vaxart, Inc.?
This is a Definitive Additional Materials filing, indicated by the checkbox next to 'Definitive Additional Materials' and the filing date of May 16, 2025.
What is Vaxart, Inc.'s primary business classification?
Vaxart, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
What is Vaxart, Inc.'s business address?
Vaxart, Inc.'s business address is 170 Harbor Way, Suite 300, South San Francisco, CA 94080.
Has Vaxart, Inc. undergone name changes in the past?
Yes, Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc. (name change April 13, 2016), Biota Pharmaceuticals, Inc. (name change November 13, 2012), and NABI BIOPHARMACEUTICALS (name change July 19, 2010).
What is the SEC file number for Vaxart, Inc.?
The SEC file number for Vaxart, Inc. is 001-35285.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 16, 2025 regarding Vaxart, Inc. (VXRT).